Precision medicine


Oncology Precision System

What is O.P.S.?

KeyZell has been able to address the challenges posed by personalized medicine in oncology and take the definitive leap to effectively implement, for the first time, an innovative system that offers individualized therapies to patients.

This system is called O.P.S. (Oncology Presicion System), a SaaS (Software as a Service) tool, for continuous improvement in the decision-making of oncologists or doctors who treat cancer patients.

It is an instrument that helps predict the best personalized treatment that guarantees the highest 5-year survival rate.
Life science research

KeyZell is the company that currently leads this biomedical revolution of precision medicine worldwide.

This represents a huge opportunity for both patients and the sector in terms of economics and innovation.
Research Team Working with Supercomputer

How does the technology work?

It uses Machine Learning technology to provide the device with the ability to identify patterns and make predictions, which help oncologists choose the best treatment based on the unique characteristics of the patient, currently includes up to 112 biomarkers.

These variables are

Age, sex, tumor type and subtype, staging, metastasis, metastatic localization, PA, associated comorbidities (Charlson), use of ATB/CE. Infections, BMI, social support, etc.
Lymphocytes, neutrophils, LDH, creatinine, albumin, total proteins, GFR, etc.
Type of treatment (chemotherapy, immunotherapy, chemo-immunotherapy, tyrosine kinase inhibitors), number of treatment lines, medication, dose, and order of administration.
Overall survival, progression-free survival, objective response rate (PR+CR), disease control rate (PR+CR+EE), DoR (duration of response, measurement of delays, and measurement of side effects.
Specific variables on treatment toxicity according to cancer type such as toxicity index (TI), maximum grade and mean toxicity.


We solve your queries

Predict the best treatment for each patient that gives them the highest 5-year survival rate.

Training for the prototype for breast and lung cancer has now been completed and is now ready for production. Training the module for colon cancer.

It is currently 89% effective; however, training continues to improve its efficiency.

O.P.S. has been validated by two ethics committees in Spain and Mexico.

Smiling scientist using laptop in laboratory

Image diagnosis

We lead the Precision Medicine biomedical revolution

This represents a huge opportunity for both patients and the sector in terms of economics and innovation